hyoscyamine has been researched along with clavulanic acid in 1 studies
| Studies (hyoscyamine) | Trials (hyoscyamine) | Recent Studies (post-2010) (hyoscyamine) | Studies (clavulanic acid) | Trials (clavulanic acid) | Recent Studies (post-2010) (clavulanic acid) |
|---|---|---|---|---|---|
| 99 | 1 | 55 | 1,801 | 212 | 424 |
| Protein | Taxonomy | hyoscyamine (IC50) | clavulanic acid (IC50) |
|---|---|---|---|
| Beta-lactamase | Klebsiella pneumoniae | 1.72 | |
| Beta-lactamase | Escherichia coli | 0.07 | |
| Beta-lactamase | Citrobacter gillenii | 0.009 | |
| Beta-lactamase | Shouchella clausii | 0.085 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Staphylococcus aureus | 0.08 | |
| Beta-lactamase | Escherichia coli K-12 | 0.015 | |
| Beta-lactamase SHV-1 | Escherichia coli | 0.028 | |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | 0.17 | |
| Beta-lactamase OXA-1 | Escherichia coli | 3.2 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 0.17 | |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | 0.8 | |
| Beta-lactamase TEM | Escherichia coli | 0.0933 | |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | 0.01 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Klebsiella pneumoniae | 0.02 | |
| Class D beta-lactamase | Brachyspira pilosicoli | 2 | |
| Beta-lactamase | Pseudomonas luteola | 0.036 | |
| Beta-lactamase | Escherichia coli | 8.6 | |
| Beta-lactamase | Escherichia coli | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
1 other study(ies) available for hyoscyamine and clavulanic acid
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |